Baird Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $42
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Brian Skorney initiates coverage on Regenxbio (NASDAQ:RGNX) with an Outperform rating and announces a price target of $42.
June 02, 2023 | 8:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regenxbio receives an Outperform rating and a $42 price target from Baird analyst Brian Skorney.
The Outperform rating and $42 price target from Baird analyst Brian Skorney indicate a positive outlook for Regenxbio's stock in the short term. This news is directly related to RGNX and is important for investors as it suggests potential growth in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100